Ligthelm 2011.
Study characteristics | |||
Patient Sampling | Cross‐sectional, consecutive, prospective | ||
Patient characteristics and setting | Presenting signs and symptoms: patients with suspicion of lymph node TB Age: < 5 years 4%; 5 to 20 years 13%; > 20 years 83% Sex, female: 58% Children: estimated < 15% HIV infection: 19% Clinical setting: university hospital (inpatient and outpatient) Past history of TB: not reported Patients on anti‐TB treatment: not reported Number of specimens evaluated: 48 Laboratory level: central Country: South Africa World Bank Income Classification: middle income High TB burden: yes High TB/HIV burden: yes High MDR‐TB burden: yes |
||
Index tests | Xpert MTB/RIF WHO SOP or manufacturer's protocol followed: yes Manufacturer's involvement: no |
||
Target condition and reference standard(s) | Target condition: lymph node TB Reference standard for TB detection: MGIT Reference standard for rifampicin resistance: MTBDRplus Speciation: yes Decontamination: no |
||
Flow and timing | |||
Comparative | |||
Notes | "It is unlikely that our patient cohort had exacerbated disease compared to patients presenting at primary health care clinics, as these patients are routinely referred from the primary health care clinic to the referral centre for FNAB (fine needle aspiration biopsy)" | ||
Methodological quality | |||
Item | Authors' judgement | Risk of bias | Applicability concerns |
DOMAIN 1: Patient Selection | |||
Was a consecutive or random sample of patients enrolled? | Yes | ||
Was a case‐control design avoided? | Yes | ||
Did the study avoid inappropriate exclusions? | Yes | ||
Could the selection of patients have introduced bias? | Low risk | ||
Are there concerns that the included patients and setting do not match the review question? | Unclear | ||
DOMAIN 2: Index Test (Xpert MTB/RIF) | |||
Were the index test results interpreted without knowledge of the results of the reference standard? | Yes | ||
If a threshold was used, was it pre‐specified? | Yes | ||
Could the conduct or interpretation of the index test have introduced bias? | Low risk | ||
Are there concerns that the index test, its conduct, or interpretation differ from the review question? | Low concern | ||
DOMAIN 2: Index Test (Xpert Ultra) | |||
DOMAIN 3: Reference Standard | |||
Is the reference standards likely to correctly classify the target condition? | Yes | ||
Were the reference standard results interpreted without knowledge of the results of the index tests? | Yes | ||
For rifampicin resistance testing, were the reference standard results interpreted without knowledge of the results of the index test? | Yes | ||
Could the reference standard, its conduct, or its interpretation have introduced bias? | Low risk | ||
Are there concerns that the target condition as defined by the reference standard does not match the question? | Low concern | ||
DOMAIN 4: Flow and Timing | |||
Was there an appropriate interval between index test and reference standard? | Yes | ||
Did all patients receive the same reference standard? | Yes | ||
Were all patients included in the analysis? | Yes | ||
Could the patient flow have introduced bias? | Low risk |